Navigation Links
Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
Date:10/28/2010

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the third quarter ended September 30,2010 on Wednesday, November 3, 2010 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (800) 884-5695 (domestic) or (617) 786-2960 (international), participant code 70229939. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The U.S. Food and Drug Administration (FDA) has scheduled the Endocrinologic and Metabolic Drugs Advisory Committee meeting on December 7, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LAKES, N.J. , Jan. 18, 2017 BD (Becton, ... technology company, announced today that it will host a live webcast ... at 1 p.m. (ET). The webcast can be ... be available for replay through Tuesday, January 31, 2017. ... About BD BD ...
(Date:1/18/2017)... 2017 Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced that Dr. ... of Applied BioMath, will present at the next ... Meeting on Thursday January 19, 2017 at the ... MA.   Dr. Burke,s talk "Quantitative Modeling and Simulation ...
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse Labs ... Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables / ... planned for further growth in 2017. Extractable & Leachable evaluations have become increasingly ...
(Date:1/18/2017)... KING OF PRUSSIA, PA (PRWEB) , ... January ... ... to disrupt clinical operations again at the CHI SCOPE Summit for Clinical Ops ... and AstraZeneca in engaging panel discussions to examine vital clinical research issues such ...
Breaking Biology Technology:
(Date:1/6/2017)... 5, 2017  SomaLogic announced today that it ... established by iCarbonX, the China ... "Global Digital Health Ecosystem that can define each ... individual,s biological, behavioral and psychological data, the Internet ... companies, SomaLogic will provide proteomics data and applications ...
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
Breaking Biology News(10 mins):